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In recent  months,  pharmaco-vigilance  alerts  have  emerged  for  dronedarone,  followed  by
discontinuation  of  the  Permanent  Atrial  ﬁbriLLAtion  Outcome  Study  Using  Dronedarone  on
Top  of  Standard  Therapy  (PALLAS)  study  in  July  2011.  The  recent  publication  of  this  study
[1]  undoubtedly  leads  us  to  question  the  current  position  of  this  antiarrhythmic  drug,  but
also  to  analyse  the  currently  available  treatments  for  permanent  atrial  ﬁbrillation  (AF).
Permanent atrial ﬁbrillation
Permanent  AF  —  the  ﬁnal  stage  within  the  AF  continuum  —  is  not  yet  well  understood.  It
is  only  recently,  that  data  from  some  large  registries  [2,3]  and  a  few  randomized  studies
[4,5]  have  become  available.  However,  of  the  three  forms  of  AF  —  paroxysmal,  persistent,
and  permanent  —  permanent  AF  is  the  most  common,  representing  nearly  50%  of  cases,
when  excluding  ‘‘ﬁrst  access’’  AF.  Compared  with  paroxysmal  AF,  permanent  AF  tends
to  occur  in  older  patients  (more  than  70  years  of  age  on  average  versus  65  years  for
the  other  forms  of  AF);  as  many  as  30—40%  of  AF  patients  over  75  years  of  age  can  have
permanent  AF.  When  compared  with  paroxysmal  AF,  the  prevalence  of  hypertension  is
similar,  that  of  diabetes  is  twice  as  frequent  (17—28%  of  patients),  and  that  for  structural
heart  diseases  (ishaemic,  non-ischaemic,  valvular)  is  greater.  Not  surprisingly,  the  average
CHADS2 score  is  higher  in  patients  with  permanent  AF,  calculated  at  between  1.8  and  2.2,
against  0.9—1.7  for  paroxysmal  AF.
At  ﬁrst  glance,  the  therapeutic  approach  in  permanent  AF  may  appear  simple.  By
deﬁnition,  there  is  no  room  for  any  ‘‘rhythm-control’’  strategy;  antithrombotic  guide-
lines  are  well  established  with  regard  to  risk  scores  and  they  do  not  include  AF  forms.
For  a  ‘‘rate-control’’  strategy,  the  medications  are  beta-blockers,  calcium-channel  block-
ers  and  digoxin,  proposed  in  international  guidelines  as  class  I  indications  with  a  level
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f  evidence  A  [6,7]. When  adequate  rate  control  is  not
btained  with  such  medications,  the  next  step  is  atrioven-
ricular  node  ablation,  performed  in  1—5%  of  patients,
ombined  with  permanent  right  ventricular  pacing,  up-
raded  to  biventricular  pacing  in  the  presence  of  heart
ailure,  ventricular  dilatation  and  left  bundle  branch  block.
owever,  two  questions  remain  about  the  rate-control
trategy.
First,  the  drugs  available  are  perhaps  suboptimal,  digoxin
se  remains  controversial,  and  registries  consistently  report
he  use  of  antiarrhythmic  drugs  in  5—10%  of  patients
ith  permanent  AF.  Indeed,  in  the  2010  guidelines  [6],
miodarone  use  was  considered  possible  (class  IIB)  while
ronedarone  even  appeared  as  a  class  IIA  recommendation.
Second,  the  ‘‘ideal’’  ventricular  rate  is  not  yet  known.
ndeed,  the  latest  recommendations  offer  two  rate-control
trategies:  a  ‘‘lenient’’  rate  control  (less  than  110  beats
er  minute)  in  asymptomatic  patients  and  a  ‘‘strict’’  rate
ontrol  (less  than  80  beats  per  minute)  in  symptomatic
atients  or  in  those  with  heart  failure.  However,  Canadian
nd  US  guidelines,  prudently,  retain  a  maximum  ventricular
ate  of  100  beats  per  minute  in  asymptomatic  patients  [7].
ndeed,  sub  analysis  studies  have  shown  that,  paradoxically,
he  beneﬁt  of  the  rate-control  strategy  was  independent  of
he  ventricular  rate  obtained.  As  a  result,  a  study  comparing
‘lenient’’  with  ‘‘strict’’  rate  control  was  performed  in  614
atients  with  permanent  AF  and  rapid  ventricular  rates
espite  usual  treatment  (more  than  80  beats  per  minute).
o  differences  were  found  between  the  two  strategies,  but
his  small  study,  which  used  a  composite  endpoint,  is  not
ithout  any  critic.
he Permanent Atrial ﬁbriLLAtion
utcome Study Using Dronedarone on Top
f  Standard Therapy (PALLAS) study
he  speciﬁc  objective  of  the  PALLAS  study  [1]  was  to
valuate  the  impact  of  dronedarone  on  the  hard  endpoints
f  mortality  and  cardiovascular  morbidity  in  a  very  large
lanned  cohort  of  10,800  patients.
The  PALLAS  study  began  in  July  2010,  and  was  stopped  for
afety  reasons  a  year  later.  This  study  focused  on  patients
ho  had  had  permanent  AF  for  at  least  6  months  and
ere  at  high  cardiovascular  risk:  more  than  65  years  of
ge  with  ischaemic  heart  disease,  a  history  of  stroke  or
eripheral  artery  disease,  or  more  than  75  years  of  age
ith  hypertension  and  diabetes.  Patients  were  randomized
o  receive,  in  addition  to  their  usual  treatment,  placebo
r  dronedarone  400  mg  twice  daily.  The  planned  follow-up
as  2—3  years,  driven  by  events  (≥  844  events)  from  two
o-primary  endpoints,  the  ﬁrst  being  ‘‘cardiovascular  mor-
ality  or  myocardial  infarction  or  stroke’’,  and  the  second
eing  ‘‘overall  mortality  or  hospitalization  for  cardiovascu-
ar  causes’’.
After  a  mean  follow-up  of  3.5  months  and  the  inclu-
ion  of  3236  patients,  the  study  had  to  be  stopped  for  an
xcess  of  events,  43  with  dronedarone  versus  19  for  placebo
or  the  ﬁrst  outcome,  and  127  versus  67,  respectively,  for
he  second  outcome.  The  three  main  cardiovascular  events
ere  heart  failure  hospitalization  or  episode  (n  =  115  vs.  55),
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ardiovascular  mortality  (n  =  21  vs.  10),  and  stroke  (n  =  23
s.  10)  in  the  dronedarone  group  versus  the  placebo  group.
he  usual  effects  of  the  drug  were  nevertheless  found,
xhibiting  decreases  in  ventricular  rate  (—7.6  beats  per
inute)  and  systolic  arterial  pressure  (—3.5  mmHg)  and  a
mall  increase  in  QTc  (+8  ms).  But  even  during  this  short
ollow-up,  tolerance  was  not  satisfactory  as  the  rate  of  pre-
ature  discontinuation  was  high,  at  21%,  with  side  effects
ncluding  usual  digestive  disorders  along  with  leg  oedema
nd  dyspnoea.
The  results  from  the  PALLAS  trial  are  the  exact  oppo-
ite  of  those  from  the  ATHENA  study  [8].  The  latter
howed  a  remarkable  20—30%  decrease  in  several  morbidity
nd  mortality  endpoints  (cardiovascular  death,  myocardial
nfarction,  cardiovascular  hospitalization,  hospitalization
or  AF),  while  the  ﬁndings  from  PALLAS  were  negative,  with
 highly  signiﬁcant  hazard  ratio  of  2—3.
hy do the results from PALLAS differ
rom  those of ATHENA?
s  shown  in  Table  1  [9],  patients  in  PALLAS  were  at  higher
ardiovascular  risk  in  terms  of  age,  cardiovascular  risk  fac-
ors,  underlying  heart  disease  and  history  of  heart  failure;
nly  some  had  a  low  ejection  fraction  (below  45%  or  40%):
2%  in  ATHENA  and  21%  in  PALLAS;  use  of  treatments  was
imilar  in  the  two  studies,  but  with  a  greater  use  of  anti-
oagulant  therapy  in  PALLAS.  All  subgroup  analyses  were
egative,  including  those  for  age,  history  of  heart  failure,
jection  fraction  and  heart  disease.  It  is  not  possible  to
ttribute  the  negative  results  of  PALLAS  to  some  higher-risk
ubgroup  of  patients,  and  similarly  the  beneﬁts  in  ATHENA
ere  present  in  all  subgroups  and  did  not  decrease  in  higher-
isk  patients.
The  only  signiﬁcant  interaction  was  with  digoxin,
eceived  by  one-third  of  the  patients  in  PALLAS  and  clearly
ssociated  with  a mortality  increase;  the  known  phar-
acokinetic  interaction  of  digoxin  and  dronedarone  was
robably  deleterious  in  this  population.  Another  point  con-
erns  the  very  rapid  occurrence  of  the  events,  including
hose  of  the  ﬁrst  primary  outcome:  most  strokes  occurred
uring  the  ﬁrst  month,  without  clear  explanation:  systolic
lood  pressure  decreased,  and  the  quality  of  anticoagula-
ion  at  baseline  was  not  an  issue.  The  high  discontinuation
ates,  in  the  treatment  group  (21%)  but  also  in  the  placebo
roup  (11%),  evoke  a  frail  population.  Regarding  the  second
rimary  endpoint,  the  large  number  of  heart  failure  events
ay  indicate  a  negative  inotropic  effect  of  dronedarone,  sig-
iﬁcant  in  this  population  of  elderly  patients  treated  with  a
niform  and  standard  dose  of  800  mg  per  day.
The  rationale  of  the  PALLAS  study  should  also  be
uestioned,  as  was  the  rationale  of  another  negative
tudy  (ANDROMEDA)  [10], which  involved  treatment  with
ronedarone  in  patients  without  atrial  arrhythmia  but  with
eart  failure  with  a  low  ejection  fraction  and  recent  (less
han  1  month)  left  ventricular  decompensation.  Indeed,
ALLAS  was  not  a  rhythm-control  study  because  the  atrial
rrhythmia  was  already  permanent,  nor  was  it  a  rate-control
tudy  because  the  ventricular  rate  was  not  particularly  fast,
ut  only  an  add-on  use  of  an  antiarrhythmic  drug  in  patients
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Table  1  Comparison  of  the  ATHENA,  PALLAS  and  ANDROMEDA  populations.
Variable  ATHENA  PALLAS  ANDROMEDA
Patient  demographic  and  clinical  characteristics
Age,  mean  (years)  72  75  72
Women  (%)  47  35  25
Baseline  atrial  ﬁbrillation  (%)  25  100  25
Hypertension  (%) 86  83  37
Coronary  artery  disease  (%) 30 41 65
CHF  class  II  or  III  (%) 21 54 97
Treatment  (%)
Beta-blocker  71  74  61
Digoxin  14  33  31
ACE  or  ARB  70  78  86
Oral  anticoagulant  60  84  31
Outcome Hazard  ratio %
All-cause  death  0.84  1.94  2.13
Cardiovascular  death  0.71  2.11  2.75
Death  for  arrhythmia  0.55  3.26  1.68
Stroke  0.66  2.32  NA
CHF  (hospitalization  or  event) 0.86 1.89  1.22
Nattel S. [9].
ACE: angiotensin-converting enzyme; ARB: angiotensin receptor blocker; CHF: congestive heart failure.
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Rat  high  cardiovascular  risk.  Indeed,  the  success  of  ATHENA
has  suggested  several  mechanisms  for  the  drug,  along  with
rhythm-  and  rate-control  beneﬁts,  such  as  hypotensive  and
antianginal  effects  due  to  the  properties  of  beta-blockers
and  calcium-channel  blockers;  so  a  post-hoc  subgroup  of  343
patients  with  permanent  AF  in  ATHENA  also  beneﬁted  from
the  drug  [11]. But  the  true  question  in  permanent  AF—  an
undeniable  public  health  problem  —  is  ‘‘rate  control’’,  and
it  might  have  been  better  to  select  only  those  patients  with
a  rapid  ventricular  rate,  for  example  more  than  80  beats
per  minute,  as  in  two  previous  ‘‘rate  control’’  drug  trials
[4,5].  The  question  of  the  optimal  rate  remains  relevant,
and  signiﬁcantly  the  success  of  ivabradine  in  heart  failure
was  shown  in  patients  with  a  rapid  ventricular  rate  (more
than  70  beats  per  minute)  in  sinus  rhythm  [12]. Finally,  we  do
not  know  what  the  results  will  be  of  a  randomized  controlled
trial  of  digoxin  or  calcium-channel  blockers  in  a  PALLAS-like
population.
What remains now for dronedarone?
The  indications  of  dronedarone  in  paroxysmal  or  persistent
AF  have  recently  been  restricted,  excluding  any  patient
with  a  history  of  heart  failure  or  left  ventricular  dysfunc-
tion,  along  with  any  patients  with  previous  liver  or  lung
intolerance  on  amiodarone,  and  those  with  permanent  AF
[13].  However,  the  levels  of  evidence  of  PALLAS  —a  warning
signal  carried  by  a  prematurely  stopped  study  —could  not  be
compared  with  those  of  ATHENA,  which  involved  4600  high
cardiovascular  risk  patients  with  up  to  30  months  of  follow-
up:  for  example,  the  ischaemic  patient  with  a  maintained
left  ventricular  function  and  paroxysmal  or  persistent  AF
may  be  now  the  ideal  recipient  of  dronedarone.The  role  of  dronedarone  in  the  antiarrhythmic  arma-
entarium  will  probably  be  clariﬁed  in  the  coming  years,
imilarly  to  class  I  antiarrhythmic  drugs,  which,  despite
he  Cardiac  Arrhythmia  Suppression  Trial  (CAST)  study  [14],
ave  gradually  found  their  place  conﬁrmed  by  recent  inter-
ational  registries  of  patients  with  paroxysmal  or  persistent
F  [15]. Dronedarone  has  indeed  been  widely  studied  in
housands  of  patients  in  several  studies,  which  it  is  not
he  case  with  currently  available  but  older  antiarrhythmic
rugs.  On  the  contrary,  amiodarone,  rightly  acclaimed  for  its
emarkable  efﬁcacy  and  cardiac  tolerance,  still  raises  some
oubts,  demonstrated  by  the  lack  of  any  long-term  beneﬁt
n  morbidity  and  mortality  shown  in  several  meta-analysis.
So,  let’s  trust  that  despite  the  ﬁndings  from  PALLAS,  the
‘odyssey’’  of  dronedarone  [16]  will  continue.
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